Clinical trial NCT01204164: Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Official title: Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: AML
ALL
Blast Crisis
MDS
Multiple Myeloma
Keywords: AML
ALL
MDS
CML in blast crisis
Multiple Myeloma
Carfilzomib refractory
Lead sponsor: Tragara Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2010-09-17
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open-label, dose escalation Phase 1 study.

Detailed description: This is a multicenter, open-label, dose escalation, Phase 1/1b study.

For Parts 1, 2, and 3 of the study, the primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with different types of hematological malignancy.

For Part 4, the primary objective is to evaluate the safety and tolerability of once-weekly dosing at the maximum-tolerated dose/ Recommended Phase 2 Dose of TG02 in combination with carfilzomib.

This study consists of four parts:

* Part 1: single agent TG02 in acute leukemia patients
* Part 2: single agent TG02 in multiple myeloma patients
* Part 3: TG02 in combination with carfilzomib in multiple myeloma patients
* Part 4: TG02 in combination with carfilzomib in carfilzomib refractory multiple myeloma patients.

Eligibility criteria: Part 1 Inclusion Criteria:

* Relapsed AML, ALL, CML in blast crisis, or MDS
* 65+ yrs with AML not eligible for standard frontline chemo
* Interval from prior treatment to time of study drug at least 5 half-lives for cytotoxic/ noncytotoxic agents.
* Persistent clinically significant toxicities from prior chemo ≤ Grd 1
* ECOG PS 0-2
* Lab values:

  * Cr ≤ 2X ULN
  * ALT and/or AST ≤2.5 X ULN
  * Total bilirubin ≤1.5 X ULN unless considered due to Gilbert's syndrome
* Negative pregnancy test
* Can take oral med

Part 2 Inclusion Criteria:

* Relapsed multiple myeloma. At least ≥1 line of therapy and progressed after ≥1 prior therapy
* Measurable disease defined as at least one of the following:

  * Serum M ≥500 mg/dL
  * Urine M ≥200 mg per 24hr
  * Involved FLC ≥10 mg/dL and abnormal FLC ratio in serum (\<0.26 or \>1.65)
  * Measurable soft tissue plasmacytoma
* Persistent clinically significant toxicities from prior chemo ≤ Grd 1
* ECOG PS 0-2
* Lab values:

  * ANC of \>1000/mm3
  * Platelets ≥50,000/mm3
  * Cr ≤2X the ULN
  * ALT and/or AST ≤2.5X ULN
  * Total bilirubin ≤1.5X ULN, unless considered due to Gilbert's syndrome
* Negative pregnancy test
* Can take oral med

Part 3 Inclusion Criteria:

* Measurable disease defined as at least one of the following:

  * Serum M ≥500 mg/dL
  * Urine M protein ≥200 mg per 24hr
  * Involved FLC level ≥10 mg/dL and abnormal FLC ratio in serum (\<0.26 or \>1.65)
* Meet at least one of the criteria below:

  * a. ≥2 prior therapies including proteasome inhibitor and immunomodulatory agent (IMiD)
  * b. ≥1 prior therapy and one of the following abnormalities: 17p del, p53, 1q amp, 1p del, t(4;14)
* Interval from prior treatment to time of study drug at least 5 half-lives or 3 wks, which ever is shorter, for noncytotoxic agents
* Persistent clinically significant toxicities from prior chemo ≤ Grd 1 or Grd 2 neuropathy without pain
* ECOG PS 0-2
* Lab values:

  * ANC of \>1000/mm3 independent of G-CSF
  * Platelets ≥50,000/mm3 independent of transfusion
  * MDRD calculated or measured CrCl of ≥30 mL/min
  * ALT and/or AST ≤3X ULN
  * Total bilirubin ≤2X ULN, unless considered due to Gilbert's syndrome
* Negative pregnancy test
* Can take oral med

Part 4 Inclusion Criteria:

* Measurable disease defined as at least one of the following:

  * Serum M ≥500 mg/dL
  * Urine M protein ≥200 mg per 24hr
  * Involved FLC level ≥10 mg/dL and an abnormal FLC ratio in serum (\<0.26 or \>1.65)
* Received prior therapies including:

  * a. bortezomib
  * b. an IMiD
  * c. carfilzomib. Demonstrated disease progression on or within 60d of completion of carfilzomib therapy
* Interval from prior treatment to time of study drug at least 5 half-lives or 3 wks, which ever is shorter, for noncytotoxic agents.
* Persistent clinically significant toxicities from prior chemo ≤ Grd 1, or Grd 2 neuropathy without pain.
* ECOG PS 0-2
* Lab values:

  * ANC of \>1000/mm3 independent of G-CSF
  * Platelets ≥50,000/mm3 independent of transfusion
  * MDRD calculated or measured CrCl of ≥30 mL/min
  * ALT and/or AST ≤3X ULN
  * Total bilirubin ≤2X ULN, unless considered due to Gilbert's syndrome
* Negative pregnancy test
* Can take oral med

Parts 1 and 2 Exclusion Criteria:

* Previous allogenic hematopoietic transplant within 90 d
* Concurrent severe or uncontrolled medical disease that would compromise the safety or compromise the ability of the patient to complete the study
* Prolonged QTC interval \>450ms
* Symptomatic CNS metastases
* Known HIV or AIDS
* Actively treated for a second malignancy
* Pregnant or nursing women

Part 3 Exclusion Criteria:

* Multiple myeloma of IgM subtype, POEMS, plasma cell leukemia
* Corticosteroids discontinued ≥7 days of initiating therapy
* Previous chemo within 2 wks
* Hx of ventricular arrhythmia or symptomatic conduction abnormality within 12m
* CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, myocardial infarction within 6m
* Prolonged QTc interval (males \>450ms, females \>470ms)
* Previous allogeneic hematopoietic transplant within 90 days of study enrollment, Active GVHD requiring treatment.
* Concurrent severe or uncontrolled medical disease that would compromise the safety or compromise the ability of the patient to complete the study
* Symptomatic CNS metastases
* Known HIV or AIDS
* Prior or 2nd malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with PSA of less than or equal to 0.1 ng/ml), or other cancer for which the subject has received curative therapy at least 3 yrs prior to study entry
* Treatment-related MDS
* Significant neuropathy (Grd 3-4 or Grd 2 with pain) at the time of 1st dose
* Primary AL amyloidosis
* Pleural effusions requiring thoracentesis or ascites requiring paracentesis
* Pregnant or nursing women

Part 4 Exclusion Criteria:

* Multiple myeloma of IgM subtype, POEMS, plasma cell leukemia
* Previous chemo within 2 wks
* Hx ventricular arrhythmia or symptomatic conduction abnormality within 12m
* CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, and myocardial infarction within 6m
* Prolonged QTc interval (males \>450ms, females \>470ms)
* Previous allogeneic hematopoietic transplant within 90 days. Active GVHD requiring treatment
* Concurrent severe or uncontrolled medical disease that would compromise the safety or compromise the ability of the patient to complete study
* Symptomatic CNS metastases
* Known HIV or AIDS
* Prior or 2nd malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with PSA of less than or equal to 0.1 ng/ml), or other cancer for which the subject has received curative therapy at least 3 yrs prior to study entry
* Treatment-related MDS
* Significant neuropathy (Grd 3-4 or Grd 2 with pain) at the time of 1st dose
* Primary AL amyloidosis
* Pleural effusions requiring thoracentesis or ascites requiring paracentesis
* Pregnant or nursing women

Primary outcomes:
measure: Maximum Tolerated Dose
timeFrame: 28 days
Secondary outcomes:
measure: Safety
timeFrame: 28 days
measure: Pharmacokinetics of TG02
timeFrame: 28 days
measure: Clinical Benefit Response
timeFrame: 28 days
measure: Overall Response Rate
timeFrame: 28 days
measure: Progression-Free Survival
timeFrame: 28 days
measure: Overall Survival
timeFrame: 28 days
measure: Duration of Response
timeFrame: 28 days
measure: Pharmacodynamics
timeFrame: 28 days
Other outcomes:
Locations:
city: Denver
country: United States
facility: RMCC
state: Colorado
city: Atlanta
country: United States
facility: Emory
state: Georgia
city: Chicago
country: United States
facility: Rush
state: Illinois
city: Indianapolis
country: United States
facility: IU
state: Indiana
city: Hackensack
country: United States
facility: HUMC
state: New Jersey
city: New York City
country: United States
facility: Cornell
state: New York
city: Columbus
country: United States
facility: OSU
state: Ohio
city: Nashville
country: United States
facility: SCRI
state: Tennessee
city: Houston
country: United States
facility: MDACC
state: Texas
Study officials:
affiliation: Tragara Pharmaceuticals
name: T Parrott
role: STUDY_DIRECTOR
References: